Preclinical Evaluation of Soluble Epoxide Hydrolase Inhibitor AMHDU against Neuropathic Pain
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25168841 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Denis Babkov und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology & Bioinformatics, Scientific Center for Innovative Drugs, Volgograd State Medical University, Volgograd 400131, Russia. Hauptthemen laut MEDLINE: Epoxide Hydrolases, Neuralgia, Analgesics. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIEHS NIH HHS, Russian Science Foundation, Ministry of Health of Russian Federation.
Abstract (Originalsprache)
Inhibition of soluble epoxide hydrolase (sEH) is a promising therapeutic strategy for treating neuropathic pain. These inhibitors effectively reduce diabetic neuropathic pain and inflammation induced by Freund’s adjuvant which makes them a suitable alternative to traditional opioids. This study showcased the notable analgesic effects of compound AMHDU (1,1′-(hexane-1,6-diyl)bis(3-((adamantan-1-yl)methyl)urea)) in both inflammatory and diabetic neuropathy models. While lacking anti-inflammatory properties in a paw edema model, AMHDU is comparable to celecoxib as an analgesic in 30 mg/kg dose administrated by intraperitoneal injection. In a diabetic tactile allodynia model, AMHDU showed a prominent analgesic activity in 10 mg/kg intraperitoneal dose (p < 0.05). The effect is comparable to that of gabapentin, but without the risk of dependence due to a different mechanism of action. Low acute oral toxicity (>2000 mg/kg) and a high therapeutic index makes AMHDU a promising candidate for further structure optimization and preclinical evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology & Bioinformatics, Scientific Center for Innovative Drugs, Volgograd State Medical University, Volgograd 400131, Russia.
- Department of Organic Chemistry, Volgograd State Technical University, Volgograd 400005, Russia.
- Department of Entomology and Nematology, UC Davis Comprehensive Cancer Center, University of California Davis, Davis, CA 95616, USA.
ORCID-Profile: Denis Babkov, Christophe Morisseau, Bruce D Hammock, Vladimir Burmistrov
Förderung
- NIEHS NIH HHS
- Russian Science Foundation
- Ministry of Health of Russian Federation
- NIH–NIEHS (RIVER Award)
- Juvenile Diabetes Research Foundation (JDRF) Grant
Zitieren
APA
Babkov, D., Eliseeva, N., Adzhienko, K., Bagmetova, V., Danilov, D., McReynolds, C. B., Morisseau, C., Hammock, B. D., & Burmistrov, V. (2024). Preclinical Evaluation of Soluble Epoxide Hydrolase Inhibitor AMHDU against Neuropathic Pain. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25168841
Vancouver
Babkov D, Eliseeva N, Adzhienko K, Bagmetova V, Danilov D, McReynolds CB, et al. Preclinical Evaluation of Soluble Epoxide Hydrolase Inhibitor AMHDU against Neuropathic Pain. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25168841
BibTeX
@article{Babkov2024,
author = {Babkov, Denis and Eliseeva, Natalya and Adzhienko, Kristina and Bagmetova, Viktoria and Danilov, Dmitry and McReynolds, Cynthia B and Morisseau, Christophe and Hammock, Bruce D and Burmistrov, Vladimir},
title = {Preclinical Evaluation of Soluble Epoxide Hydrolase Inhibitor AMHDU against Neuropathic Pain},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25168841}
}
EUVIMED